These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3032288)

  • 1. [The use of 1H-NMR-spectroscopy for the study of peptide degradation by angiotensin-converting enzyme].
    Sakharov IIu; Isakova OL; Sepetov NF; Bespalova ZhD; Ruuge EK
    Biokhimiia; 1987 Feb; 52(2):311-6. PubMed ID: 3032288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study of peptide degradation in the serum by 1H-NMR].
    Isakova OL; Sepetov NF; Bespalova ZhD; Bushuev VN; Vinogradov VA
    Bioorg Khim; 1986 Jan; 12(1):106-11. PubMed ID: 3947404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Degradation of dalargin and its analogs in the brush border membranes of rat enterocytes studied by 1H-NMR spectroscopy].
    Sepetov NF; Isakova OL; Pekelis BL; Suraeva NM
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1986; 9(2):86-9. PubMed ID: 3801146
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacokinetics of dalargin].
    Kalenikova EI; Dmitrieva OF; Korobov NV; Zhukovskiĭ SV; Tishchenko VA
    Vopr Med Khim; 1988; 34(1):75-83. PubMed ID: 3369130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bioavailability of dalargin and its metabolism during intranasal administration to rats].
    Vinogradov VA; Kalenikova EI; Sokolov AS
    Biull Eksp Biol Med; 1988 Jul; 106(7):48-50. PubMed ID: 3401577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The inhibitory effect of the synthetic leu-enkephalin analog dalargin on carcinogenesis].
    Anisimov VN; Bortkevich SM
    Vopr Onkol; 1990; 36(5):556-9. PubMed ID: 2378078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies to dalargin--a synthetic analog of enkephalins.
    Ananyeva NM; Tischenko VA; Bespalova JD; Pekelis BL; Yakubov LZ; Vinogradov VA; Rokhlin OV; Titov MI
    Immunol Lett; 1988 Aug; 18(4):269-73. PubMed ID: 3182012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of hydrolysis of [leu]enkephalin and D-ala2-[L-leu]enkephalin in rat plasma.
    Weinberger SB; Martinez JL
    J Pharmacol Exp Ther; 1988 Oct; 247(1):129-35. PubMed ID: 2902210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the hydrolysis of enkephalin congeners by the two domains of angiotensin converting enzyme.
    Deddish PA; Jackman HL; Skidgel RA; Erdös EG
    Biochem Pharmacol; 1997 May; 53(10):1459-63. PubMed ID: 9260873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High enkephalyl peptide degradation, due to angiotensin-converting enzyme-like activity in human CSF.
    Lantz I; Terenius L
    FEBS Lett; 1985 Nov; 193(1):31-4. PubMed ID: 2998876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Isolation and molecular kinetic properties of the angiotensin-converting enzyme from the human heart].
    Sakharov IIu; Danilov SM; Dukhanina EA
    Biokhimiia; 1986 Nov; 51(11):1836-42. PubMed ID: 3026499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrophilic interaction liquid chromatography for dalargin separation from its structural analogues and side products.
    Abbood A; Smadja C; Taverna M; Herrenknecht C
    J Chromatogr A; 2017 May; 1498():155-162. PubMed ID: 28173925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of the synthetic endogenous opioid analog dalargin on the natural cytotoxicity of human lymphocytes].
    Aleksandrova EN; Nasonov EL; Vinogradov VA; Titov MI
    Biull Eksp Biol Med; 1988 Apr; 105(4):442-5. PubMed ID: 3359025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dalargin--an opioid-like peptide with peripheral action].
    Korobov NV
    Farmakol Toksikol; 1988; 51(4):35-8. PubMed ID: 3191970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Zinc-dependent angiotensin-converting enzyme in reactions with various enzymes].
    Kost OA; Sharafutdinov TZ; Kazinskaia NF
    Biokhimiia; 1990 Aug; 55(8):1396-401. PubMed ID: 1963088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative study by a radioreceptor method of the pharmacokinetics of opiate ligands: morphine and dalargin].
    Sergeeva MG; Dmitrieva OF; Bespalova ZhD; Zaĭtsev SV
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1986; 9(2):81-3. PubMed ID: 3801145
    [No Abstract]   [Full Text] [Related]  

  • 17. Further characterization of the in vitro hydrolysis of [Leu]- and [Met]enkephalin in rat plasma: HPLC-ECD measurement of substrate and metabolite concentrations.
    Shibanoki S; Weinberger SB; Ishikawa K; Martinez JL
    Regul Pept; 1991 Feb; 32(3):267-78. PubMed ID: 1678195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enkephalin degradation by enkephalinergic neuroblastoma cells. Involvement of angiotensin-converting-enzyme.
    Palenker J; Lentzen H; Brandt U
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Mar; 325(3):214-7. PubMed ID: 6328331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of new peptide inhibitors on the ratio of angiotensin I-converting and kinin-degrading activities of dipeptidyl carboxypeptidase (angiotensin-converting enzyme).
    Kalinina EV; Posdnev VF; Komissarova NV; Gomazkov OA
    Biochemistry (Mosc); 1997 Mar; 62(3):247-50. PubMed ID: 9275297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin converting enzyme (ACE) and neprilysin hydrolyze neuropeptides: a brief history, the beginning and follow-ups to early studies.
    Skidgel RA; Erdös EG
    Peptides; 2004 Mar; 25(3):521-5. PubMed ID: 15134871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.